Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis

Filipova, Elena; Uzunova, Katya; Kalinov, Krassimir; Vekov, Toni

doi:10.1186/s13098-017-0290-5

Diabetology & Metabolic Syndrome

Table 1 Characteristics of studies included in the analysis

From: Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis

Author, year	Study type	Duration of treatment, weeks	Treatment	Number of patients	Characteristics of patients
Author, year	Study type	Duration of treatment, weeks	Treatment	Number of patients	Mean age (years)	Gender (% female)	Mean BMI (kg/m²)	Diabetes duration (years)
Berhanu et al. [13]	randomized placebo-controlled	20	PIO + INS	110	52.9	56.4	30.7	7.7
Berhanu et al. [13]	randomized placebo-controlled	20	PLB + INS	112	52.5	58.9	31.8	8.5
Belfort et al. [14]	randomized placebo-controlled	24	PIO 45 mg	26	51	46.1	33.5	NA
Belfort et al. [14]	randomized placebo-controlled	24	PLB	21	51	70	32.9	NA
Mattoo et al. [15]	randomized, double-blind, prospective, multicenter, placebo-controlled	25	PIO 30 mg + INS	142	58.9	56.7	NA	NA
Mattoo et al. [15]		25	PLB + INS	147	58.9	56.7	NA	NA
DeFronzo et al. [16]	randomized, double-blind, placebo-controlled	125	PIO initially 30 mg after month 45 mg	303	53	42	33	Patients with IGT and IFGT
DeFronzo et al. [16]	randomized, double-blind, placebo-controlled	125	PLB	299	51.5	42	34.5	Patients with IGT and IFGT
DeFronzo et al. [17]	randomized, double-blind, placebo-controlled	125	PIO initially 30 mg after month 45 mg	213	53.9	44	33.4	Patients with IGT and IFGT
DeFronzo et al. [17]	randomized, double-blind, placebo-controlled	125	PLB	228	52.5	42	34.4	Patients with IGT and IFGT
Rosenstock et al. [18]	randomised, placebo-controlled study	16	PIO 15 mg + INS	191	56.9	53.9	33.2	NA
			PIO 30 mg + INS	188	57.5	49.5	34.3	NA
			PLB + INS	187	56.7	54.5	33.2	NA
Davidson et al. [19]	randomized, double-blind, multicenter	24	PIO 30 mg + INS	345	NA	NA	33.2	12.9
Davidson et al. [19]	randomized, double-blind, multicenter	24	PIO 45 mg + INS	345	NA	NA	33.2	12.9
Goldberg et al. [3]	randomized, double-blind, prospective, multicenter	24	PIO 30 mg for 12 weeks, then 45 mg for 12 weeks	369	55.9	46.1	33.7	3.9
Goldberg et al. [3]	randomized, double-blind, prospective, multicenter	24	ROSI 4 mg for 12 weeks, then 8 mg for 12 weeks	366	56.3	45.1	32.6	4.0
Xu et al. [20]	randomized, multicenter	48	EXE	149	NA	NA	NA	NA
			INS	149
			PIO	118
Bolli et al. [12]	multicentre, randomized, active-controlled	52	PIO 30 mg + MET 1500 mg	281	57	35.9	32.1	6.4
Bolli et al. [12]	multicentre, randomized, active-controlled	52	VIL 100 mg + MET 1500 mg	295	56.3	38.3	32.2	6.4
Gerber et al. [21]	randomized, multicenter	20	PIO 30 mg	76	NA	NA	NA	NA
			PIO 30 mg for 12 weeks then 45 mg for 8 weeks	74
			PIO 45 mg	84
Panikar et al. [22]	randomised	24	PIO 7.5 mg	77	58.2	47.4	27.6	< 2
			PIO 15 mg	80	56.6	43.7	26.6
			PIO 45 mg	80	53.7	40	25.8
Kodama et al. [23]	prospective, randomized, open-label, comparator-controlled	16	PIO	32	68.4	28.1	25.2	NA
Kodama et al. [23]	prospective, randomized, open-label, comparator-controlled	16	GLI	21	66.7	19	24.7	NA
Shah et al. [24]	randomised	12–16	INS + PIO 45 mg	12	58	16	36.7	NA
Shah et al. [24]	randomised	12–16	INS + PLB	13	58	16	36.7	NA
Yoshii et al. [25]	prospective, randomized, open-label, multicenter	96	with PIO	234	69.0	36.8	24.2	11.1
Yoshii et al. [25]	prospective, randomized, open-label, multicenter	96	without PIO	247	68.9	34.0	24.3	11.5

Back to article page

ISSN: 1758-5996

Contact us

Submission enquiries: journalsubmissions@springernature.com